Margaret House

发表

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

H. Parnes, J. Kolesar, KyungMann Kim, 2019, Cancer Prevention Research.

BCAN Think Tank session 3: Prevention of bladder cancer.

E. Messing, H. Parnes, A. Kibel, 2010, Urologic oncology.

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer

E. Messing, H. Parnes, J. Kolesar, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

H. Parnes, J. Kolesar, KyungMann Kim, 2017, Cancer Prevention Research.

A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.

H. Parnes, P. Pinto, J. Schlom, 2022, European urology focus.

Prostate cancer prevention

H. Parnes, E. Klein, A. Stephenson, 2018, Cancer Prevention and Screening.

Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs.

L. Ford, G. Samimi, E. Szabo, 2022, Cancer prevention research.

Prostate cancer prevention: agent development strategies.

H. Parnes, J. Tangrea, Margaret House, 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Prostate cancer prevention: strategies for agent development

H. Parnes, J. Tangrea, Margaret House, 2013, Current opinion in oncology.

Prostate Cancer Chemoprevention Strategies

H. Parnes, J. Tangrea, Margaret House, 2010 .

Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.

H. Parnes, J. Kagan, R. Lieberman, 2004, The Journal of urology.

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

E. Messing, H. Parnes, J. Kolesar, 2012, Cancer Prevention Research.

A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

H. Parnes, KyungMann Kim, H. Mukhtar, 2020, The Prostate.

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy

E. Messing, H. Parnes, J. Kolesar, 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance.

H. Parnes, KyungMann Kim, H. Mukhtar, 2020 .

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

H. Parnes, J. Kolesar, KyungMann Kim, 2016, American journal of clinical and experimental urology.

Strategies for chemoprevention of prostate cancer

G. Miller, G. Kelloff, E. Crawford, 1999, Prostate Cancer and Prostatic Diseases.

Feasibility of 5‐fluorouracil and imiquimod for the topical treatment of cervical intraepithelial neoplasias (CIN) 2/3

J. Bauman, Sopan Mohnot, S. O'Connor, 2023, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.